Compared with ER+/PR+ and HER2+ BC patients benefiting from endocrine and targeted therapies with chemotherapy, triple‐negative, or basal BC patients have poorer prognoses due to limited treatment options.4, 5, 6. The gene discussed is PGR; the disease is breast cancer.